Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration
Clinical trial NCT05253807 · COMPLETED
Trial details
- NCT number
- NCT05253807
- Sponsor
- Incyte Corporation
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-04-29
- Primary completion
- 2023-08-16
- Enrollment
- 8
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.